 |
PDBsum entry 2qq7
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
16:3482-3488
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
|
|
A.Michalczyk,
S.Klüter,
H.B.Rode,
J.R.Simard,
C.Grütter,
M.Rabiller,
D.Rauh.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Resistance to kinase-targeted cancer drugs has recently been linked to a single
point mutation in the ATP binding site of the kinase. In EGFR, the crucial
Thr790 gatekeeper residue is mutated to a Met and prevents reversible ATP
competitive inhibitors from binding. Irreversible 4-(phenylamino)quinazolines
have been shown to overcome this drug resistance and are currently in clinical
trials. In order to obtain a detailed structural understanding of how
irreversible inhibitors overcome drug resistance, we used Src kinase as a model
system for drug resistant EGFR-T790M. We report the first crystal structure of a
drug resistant kinase in complex with an irreversible inhibitor. This
4-(phenylamino)quinazoline inhibits wild type and drug resistant EGFR in vitro
at low nM concentrations. The co-crystal structure of drug resistant cSrc-T338M
kinase domain provides the structural basis of this activity.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Rabiller,
M.Getlik,
S.Klüter,
A.Richters,
S.Tückmantel,
J.R.Simard,
and
D.Rauh
(2010).
Proteus in the world of proteins: conformational changes in protein kinases.
|
| |
Arch Pharm (Weinheim),
343,
193-206.
|
 |
|
|
|
|
 |
R.Rajasekaran,
and
R.Sethumadhavan
(2010).
In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
|
| |
Appl Biochem Biotechnol,
160,
1723-1733.
|
 |
|
|
|
|
 |
S.Klüter,
J.R.Simard,
H.B.Rode,
C.Grütter,
V.Pawar,
H.C.Raaijmakers,
T.A.Barf,
M.Rabiller,
W.A.van Otterlo,
and
D.Rauh
(2010).
Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
|
| |
Chembiochem,
11,
2557-2566.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Li,
T.S.Kaoud,
C.Laroche,
K.N.Dalby,
and
S.M.Kerwin
(2009).
Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.
|
| |
Bioorg Med Chem Lett,
19,
6293-6297.
|
 |
|
|
|
|
 |
J.R.Simard,
S.Klüter,
C.Grütter,
M.Getlik,
M.Rabiller,
H.B.Rode,
and
D.Rauh
(2009).
A new screening assay for allosteric inhibitors of cSrc.
|
| |
Nat Chem Biol,
5,
394-396.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |